Chromosomal Instability Associated with Improved Outcomes in Breast Cancer
the Cancer Therapy Advisor take:
There is an association between extreme chromosomal instability and improved outcome in estrogen receptor (ER)-negative breast cancers, a new study published online early in the journal Annals of Oncology has shown.
Previous studies have shown that extreme chromosomal instability is associated with improved clinical outcome in patients with ER-negative breast cancer, while it has been shown to be linked with drug resistance and poor outcomes in various other cancers.
For this study, researchers analyzed 1,173 tumors form the breast cancer TACT trial by performing dual centromeric fluorescence in situ hybridization for chromosomes 2 and 15.
Results showed that during a median follow-up of 91 months, extreme chromosomal instability was associated with improved clinical outcome in patients with ER-negative breast cancer (P trend = 0.03). In addition, researchers found that increasing chromosomal instability was associated with improved outcome in patients with ER-negative/HER2-negative breast cancers (P trend = 0.007).
Identifying patients with extreme chromosomal instability may help to predict prognosis and guide treatment decisions.
Association between extreme chromosomal instability and improved outcome in ER-negative breast cancers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer